Mostrar el registro sencillo del ítem
dc.contributor.author
Maraninchi, Marie
dc.contributor.author
Calabrese, Anastasia
dc.contributor.author
Nogueira, Juan Patricio
![Se ha confirmado la validez de este valor de autoridad por un usuario](/themes/CONICETDigital/images/authority_control/invisible.gif)
dc.contributor.author
Castinetti, Frédéric
dc.contributor.author
Mancini, Julien
dc.contributor.author
Mourre, Florian
dc.contributor.author
Piétri, Léa
dc.contributor.author
Bénamo, Eric
dc.contributor.author
Albarel, Frédérique
dc.contributor.author
Morange, Isabelle
dc.contributor.author
Dupont Roussel, Jeanine
dc.contributor.author
Nicolay, Alain
dc.contributor.author
Brue, Thierry
dc.contributor.author
Béliard, Sophie
dc.contributor.author
Valéro, René
dc.date.available
2022-09-06T10:33:35Z
dc.date.issued
2021-09
dc.identifier.citation
Maraninchi, Marie; Calabrese, Anastasia; Nogueira, Juan Patricio; Castinetti, Frédéric; Mancini, Julien; et al.; Role of growth hormone in hepatic and intestinal triglyceride-rich lipoprotein metabolism; Elsevier Science Inc.; Journal Of Clinical Lipidology; 15; 5; 9-2021; 712-723
dc.identifier.issn
1933-2874
dc.identifier.uri
http://hdl.handle.net/11336/167458
dc.description.abstract
Background: Elevated plasma concentrations of hepatic- and intestinally-derived triglyceride-rich lipoproteins (TRL) are implicated in the pathogenesis of atherosclerotic cardiovascular disease and all-cause mortality. Excess of TRL is the driving cause of atherogenic dyslipidemia commonly occurring in insulin-resistant individuals such as patients with obesity, type 2 diabetes and metabolic syndrome. Interestingly, growth hormone (GH)-deficient individuals display similar atherogenic dyslipidemia, suggesting an important role of GH and GH deficiency in the regulation of TRL metabolism. Objective: We aimed to examine the direct and/or indirect role of GH on TRL metabolism. Methods: We investigated the effect on fasting and postprandial hepatic-TRL and intestinal-TRL metabolism of short-term (one month) withdrawal of GH in 10 GH-deficient adults. Results: After GH withdrawal, we found a reduction in fasting plasma TRL concentration (significant decrease in TRL-TG, TRL-cholesterol, TRL-apoB-100, TRL-apoC-III and TRL-apoC-II) but not in postprandial TRL response. This reduction was due to fewer fasting TRL particles without a change in TG per particle and was not accompanied by a change in postprandial TRL-apoB-48 response. Individual reductions in TRL correlated strongly with increases in insulin sensitivity and decreases in TRL-apoC-III. Conclusion: In this relatively short term ‘loss of function’ human experimental model, we have shown an unanticipated reduction of hepatic-TRL particles despite increase in total body fat mass and reduction in lean mass. These findings contrast with the atherogenic dyslipidemia previously described in chronic GH deficient states, providing a new perspective for the role of GH in lipoprotein metabolism.
dc.format
application/pdf
dc.language.iso
eng
dc.publisher
Elsevier Science Inc.
![Se ha confirmado la validez de este valor de autoridad por un usuario](/themes/CONICETDigital/images/authority_control/invisible.gif)
dc.rights
info:eu-repo/semantics/restrictedAccess
dc.rights.uri
https://creativecommons.org/licenses/by-nc-sa/2.5/ar/
dc.subject
GH-DEFICIENT PATIENTS
dc.subject
GROWTH HORMONE
dc.subject
INSULIN RESISTANCE
dc.subject
LIPIDS
dc.subject
TRIGLYCERIDE-RICH LIPOPROTEINS
dc.subject.classification
Endocrinología y Metabolismo
![Se ha confirmado la validez de este valor de autoridad por un usuario](/themes/CONICETDigital/images/authority_control/invisible.gif)
dc.subject.classification
Medicina Clínica
![Se ha confirmado la validez de este valor de autoridad por un usuario](/themes/CONICETDigital/images/authority_control/invisible.gif)
dc.subject.classification
CIENCIAS MÉDICAS Y DE LA SALUD
![Se ha confirmado la validez de este valor de autoridad por un usuario](/themes/CONICETDigital/images/authority_control/invisible.gif)
dc.title
Role of growth hormone in hepatic and intestinal triglyceride-rich lipoprotein metabolism
dc.type
info:eu-repo/semantics/article
dc.type
info:ar-repo/semantics/artículo
dc.type
info:eu-repo/semantics/publishedVersion
dc.date.updated
2022-08-16T20:37:15Z
dc.journal.volume
15
dc.journal.number
5
dc.journal.pagination
712-723
dc.journal.pais
Estados Unidos
![Se ha confirmado la validez de este valor de autoridad por un usuario](/themes/CONICETDigital/images/authority_control/invisible.gif)
dc.description.fil
Fil: Maraninchi, Marie. Inserm; Francia
dc.description.fil
Fil: Calabrese, Anastasia. Inserm; Francia
dc.description.fil
Fil: Nogueira, Juan Patricio. Universidad Nacional de Formosa; Argentina. Consejo Nacional de Investigaciones Científicas y Técnicas. Centro Científico Tecnológico Conicet - Nordeste; Argentina
dc.description.fil
Fil: Castinetti, Frédéric. Inserm; Francia
dc.description.fil
Fil: Mancini, Julien. Inserm; Francia
dc.description.fil
Fil: Mourre, Florian. Inserm; Francia
dc.description.fil
Fil: Piétri, Léa. Inserm; Francia
dc.description.fil
Fil: Bénamo, Eric. Inserm; Francia
dc.description.fil
Fil: Albarel, Frédérique. Inserm; Francia
dc.description.fil
Fil: Morange, Isabelle. Inserm; Francia
dc.description.fil
Fil: Dupont Roussel, Jeanine. Inserm; Francia
dc.description.fil
Fil: Nicolay, Alain. La Conception Hospital; Francia
dc.description.fil
Fil: Brue, Thierry. Inserm; Francia
dc.description.fil
Fil: Béliard, Sophie. Inserm; Francia
dc.description.fil
Fil: Valéro, René. Inserm; Francia
dc.journal.title
Journal Of Clinical Lipidology
![Se ha confirmado la validez de este valor de autoridad por un usuario](/themes/CONICETDigital/images/authority_control/invisible.gif)
dc.relation.alternativeid
info:eu-repo/semantics/altIdentifier/doi/http://dx.doi.org/10.1016/j.jacl.2021.08.003
dc.relation.alternativeid
info:eu-repo/semantics/altIdentifier/url/https://www.sciencedirect.com/science/article/pii/S1933287421001239
Archivos asociados